Clinical Trials
20 trialsNCT05735704 2025-03-26
SANGUINE
JaxBio Ltd
Unknown
NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
NCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06218771 2024-01-23
A Study of TQB3454 Tablets in Patients With Blood Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT06008405 2023-09-06
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05970822 2023-08-01
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05448599 2023-03-15
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05426798 2022-06-22
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05061147 2021-10-01
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Maxinovel Pty., Ltd.
Phase 1/2 Unknown
NCT04429191 2021-06-11
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Jasper Therapeutics, Inc.
Phase 1 Unknown
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04156256 2019-11-12
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT01211457 2019-07-16
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT02576301 2018-06-04
AML
Mateon Therapeutics
Phase 1/2 Unknown
NCT02240537 2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00596999 2012-04-10
HPDSC
Celgene
Unknown